Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.
advanced cell therapies
local therapy
mesothelioma
micro-environment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Aug 2021
20 Aug 2021
Historique:
received:
21
07
2021
revised:
06
08
2021
accepted:
17
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Malignant Pleural Mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated with asbestos exposure and still lacking effective therapies. Modern targeted biological strategies that have revolutionized the therapy of other solid tumors have not had success so far in the MPM. Combination immunotherapy might achieve better results over chemotherapy alone, but there is still a need for more effective therapeutic approaches. Based on the peculiar disease features of MPM, several strategies for local therapeutic delivery have been developed over the past years. The common rationale of these approaches is: (i) to reduce the risk of drug inactivation before reaching the target tumor cells; (ii) to increase the concentration of active drugs in the tumor micro-environment and their bioavailability; (iii) to reduce toxic effects on normal, non-transformed cells, because of much lower drug doses than those used for systemic chemotherapy. The complex interactions between drugs and the local immune-inflammatory micro-environment modulate the subsequent clinical response. In this perspective, the main interest is currently addressed to the development of local drug delivery platforms, both cell therapy and engineered nanotools. We here propose a review aimed at deep investigation of the biologic effects of the current local therapies for MPM, including cell therapies, and the mechanisms of interaction with the tumor micro-environment.
Identifiants
pubmed: 34445720
pii: ijms22169014
doi: 10.3390/ijms22169014
pmc: PMC8396500
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : IRCCS Policlinico San Mattteo
ID : #08050
Références
J Thorac Oncol. 2008 Nov;3(11):1325-31
pubmed: 18978569
Int J Clin Oncol. 2020 May;25(5):818-830
pubmed: 31549270
Lung Cancer. 2021 Jul;157:48-59
pubmed: 33972125
Lung Cancer. 2016 Nov;101:48-58
pubmed: 27794408
J Thorac Oncol. 2009 Jan;4(1):97-101
pubmed: 19096314
Eur J Pharm Sci. 2016 Jan 1;81:60-6
pubmed: 26415830
Cancer Immun. 2009 Apr 02;9:3
pubmed: 19338264
J Pharm Sci. 2004 Oct;93(10):2595-608
pubmed: 15349969
Vaccines (Basel). 2021 May 19;9(5):
pubmed: 34069348
DNA Cell Biol. 2005 May;24(5):271-82
pubmed: 15869404
J Clin Oncol. 2007 Jun 10;25(17):2406-13
pubmed: 17557954
Cancers (Basel). 2020 May 07;12(5):
pubmed: 32392897
Stem Cell Res Ther. 2021 Mar 18;12(1):192
pubmed: 33736695
Br J Cancer. 2020 Jan;122(1):52-61
pubmed: 31819191
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
BMC Cancer. 2018 Aug 15;18(1):819
pubmed: 30111297
Lancet Oncol. 2017 Sep;18(9):1261-1273
pubmed: 28729154
Eur J Med Chem. 2017 Dec 15;142:266-270
pubmed: 28800871
Int J Mol Sci. 2020 Jul 30;21(15):
pubmed: 32751556
Cancer Metastasis Rev. 2020 Jun;39(2):485-503
pubmed: 32514892
Front Oncol. 2021 Jun 11;11:684025
pubmed: 34178677
J Clin Med. 2021 Jun 02;10(11):
pubmed: 34199544
Front Immunol. 2017 Nov 20;8:1594
pubmed: 29209327
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S100-S119
pubmed: 32206576
Int J Nanomedicine. 2019 May 23;14:3773-3784
pubmed: 31213801
Ann Thorac Surg. 2021 Jan 29;:
pubmed: 33524343
EBioMedicine. 2019 Oct;48:191-202
pubmed: 31648983
Respirol Case Rep. 2016 Jan 14;4(1):28-31
pubmed: 26839699
Pathology. 2021 Jun;53(4):462-469
pubmed: 33272690
Int J Mol Sci. 2018 Mar 30;19(4):
pubmed: 29601534
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Oncoimmunology. 2016 Nov 28;6(1):e1261241
pubmed: 28197385
Ann Oncol. 2018 May 1;29(5):1258-1265
pubmed: 29514216
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32451346
Cancers (Basel). 2021 Jun 26;13(13):
pubmed: 34206956
Front Oncol. 2021 Jan 15;10:594366
pubmed: 33520706
Cancer Res. 2021 Jun 15;81(12):3319-3332
pubmed: 33863778
Stem Cell Res Ther. 2019 Aug 5;10(1):235
pubmed: 31383013
Cancers (Basel). 2021 May 24;13(11):
pubmed: 34073720
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Nat Commun. 2021 Mar 19;12(1):1751
pubmed: 33741915
Int J Nanomedicine. 2019 Jan 23;14:773-785
pubmed: 30774332
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Cancers (Basel). 2021 Jun 04;13(11):
pubmed: 34199722
Pharmaceutics. 2019 Feb 01;11(2):
pubmed: 30717104
Immunotherapy. 2018 Aug;10(11):999-1010
pubmed: 30149763
Endocr Relat Cancer. 2004 Dec;11(4):659-87
pubmed: 15613445
Medicines (Basel). 2017 Nov 23;4(4):
pubmed: 29168760
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
Thorac Cardiovasc Surg. 2021 Jun 01;:
pubmed: 34062600
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
J Oncol. 2021 Feb 27;2021:5893981
pubmed: 33727921
Cancer Genomics Proteomics. 2020 May-Jun;17(3):225-236
pubmed: 32345664
Semin Oncol. 2002 Feb;29(1):18-25
pubmed: 11836665
EBioMedicine. 2017 Oct;24:34-42
pubmed: 29037604
J Immunother Cancer. 2019 Oct 10;7(1):257
pubmed: 31601268
Int J Mol Sci. 2018 Jan 13;19(1):
pubmed: 29342862
BMC Pulm Med. 2021 May 5;21(1):148
pubmed: 33952230
Diagnostics (Basel). 2019 Sep 23;9(4):
pubmed: 31547581
Glob Cardiol Sci Pract. 2013 Nov 01;2013(3):316-42
pubmed: 24689032
J Control Release. 2017 Sep 28;262:104-117
pubmed: 28736264
Expert Opin Biol Ther. 2021 Apr;21(4):473-486
pubmed: 33176519
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Radiol Clin North Am. 2018 May;56(3):437-469
pubmed: 29622078
Ann Oncol. 2019 Dec 1;30(12):1902-1913
pubmed: 31566658
Front Immunol. 2018 Dec 05;9:2759
pubmed: 30568653
Front Oncol. 2020 Jun 03;10:777
pubmed: 32582537
J Thorac Oncol. 2018 Jan;13(1):124-133
pubmed: 29079455
Life Sci. 2020 Nov 15;261:118486
pubmed: 32976881
Curr Opin Pharmacol. 2008 Oct;8(5):627-31
pubmed: 18804182
Eur Radiol Exp. 2018 Nov 14;2(1):36
pubmed: 30426318
Elife. 2015 Jul 16;4:e04796
pubmed: 26179155
J Pharm Sci. 2019 Oct;108(10):3218-3224
pubmed: 31229434
Oncoimmunology. 2017 May 12;6(7):e1328341
pubmed: 28811970
Neoplasia. 2011 Jan;13(1):12-22
pubmed: 21245936
Ann Thorac Surg. 2011 Dec;92(6):2007-13; discussion 2013-4
pubmed: 21963198
Int J Oncol. 2019 Nov;55(5):1157-1164
pubmed: 31545419
Onco Targets Ther. 2012;5:231-6
pubmed: 23055748
Clin Cancer Res. 2005 Mar 15;11(6):2300-4
pubmed: 15788680
Transl Lung Cancer Res. 2021 Jun;10(6):2988-3000
pubmed: 34295692
Biointerphases. 2011 Jun;6(2):P1-17
pubmed: 21721837
Cancer Cell. 2003 Nov;4(5):337-41
pubmed: 14667500
Front Oncol. 2021 Mar 22;11:653497
pubmed: 33828993
Front Microbiol. 2020 Jan 10;10:2924
pubmed: 31998254
Transfus Apher Sci. 2002 Oct;27(2):183-6
pubmed: 12350054
J Control Release. 2015 Dec 28;220(Pt A):29-36
pubmed: 26476173